Revenues, Significant Customers and Concentrations of Risk

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenues, Significant Customers and Concentrations of Risk

Revenues, Significant Customers and Concentrations of Risk

We disaggregate our revenue by type of goods and services and customer location.

	Years Ended December 31,
	2021		2020		2019
Types of Goods and Services
Proprietary product sales, net	$	80,016	$	62,878	$	39,215
Partnered product sales	46,651		50,956		52,888
Total product revenue, net	126,667		113,834		92,103
Licensing and development revenue	19,623		14,466		7,529
Royalties	37,692		21,299		24,232
Total revenue, net	$	183,982	$	149,599	$	123,864
Customer Location
U.S.	$	178,290	$	145,789	$	120,231
Europe	5,692		3,810		3,463
Other	—		—		170
Total revenue, net	$	183,982	$	149,599	$	123,864

Customers from which we derive 10% or more of our total revenue are as follows: 

	Years Ended December 31,
	2021	2020	2019
Teva	42%	40%	41%
McKesson 1	13%	12%	10%
AmerisourceBergen Corporation 1	12%	12%	<10%
Cardinal Health 1	11%	11%	<10%
Covis	<10%	<10%	20%

1     Revenue from sales to distributors, net of estimated sales returns and allowances based on shipments.